IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i7d10.1007_s40264-018-0648-0.html
   My bibliography  Save this article

Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients

Author

Listed:
  • Sieta T. de Vries

    (University of Groningen, University Medical Center Groningen)

  • Petra Denig

    (University of Groningen, University Medical Center Groningen)

  • Carmen Lasheras Ruiz

    (European Organisation for Rare Diseases (Eurordis))

  • François Houÿez

    (European Organisation for Rare Diseases (Eurordis))

  • Lisa Wong

    (UCL Institute of Child Health)

  • Alastair Sutcliffe

    (UCL Institute of Child Health)

  • Peter G. M. Mol

    (University of Groningen, University Medical Center Groningen)

Abstract

Introduction Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adverse drug reactions (ADRs) to national medicines agencies and to receive drug safety information. Objective This study aimed to assess (1) European HCPs’ and patients’ interest in an app for this two-way risk communication; (2) their preferences and perceptions towards specific app characteristics; and (3) which HCPs and patients are particularly interested in the app. In addition, these aspects were studied specifically for the countries where such an app was already available, i.e. Croatia, The Netherlands, and The UK. Methods European HCPs and patients were asked to complete a web-based survey developed in the context of the Web-Recognizing Adverse Drug Reactions (Web-RADR) project. Data on app interest and preferences and perceptions towards app characteristics were analysed descriptively. Logistic regression analyses were conducted to assess the association of HCP characteristics and patient characteristics on the level of interest in the app (i.e. very interested vs. not/somewhat interested). Results In total, 399 HCPs and 656 patients completed the survey. About half of the patients (48%; ranging from 38% from The Netherlands to 54% from The UK), and 61% of the HCPs (ranging from 42% from The Netherlands to 54% from The UK) were very interested in the app. A faster means of reporting ADRs and easier access to the reporting form were the main perceived benefits. HCPs and patients who already use a health app were particularly interested in the app (HCPs: odds ratio [OR] 3.52; 95% confidence interval [CI] 1.96–6.30, patients: OR 1.64; 95% CI 1.19–2.27). Conclusions An app is positively perceived by HCPs and patients for reporting ADRs quickly and for receiving drug safety information from national medicines agencies. In particular, HCPs and patients who already use other health apps were interested in the app.

Suggested Citation

  • Sieta T. de Vries & Petra Denig & Carmen Lasheras Ruiz & François Houÿez & Lisa Wong & Alastair Sutcliffe & Peter G. M. Mol, 2018. "Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients," Drug Safety, Springer, vol. 41(7), pages 697-712, July.
    • Handle: RePEc:spr:drugsa:v:41:y:2018:i:7:d:10.1007_s40264-018-0648-0
    DOI: 10.1007/s40264-018-0648-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0648-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0648-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Sieta T. Vries & Lisa Wong & Alastair Sutcliffe & François Houÿez & Carmen Lasheras Ruiz & Peter G. M. Mol, 2017. "Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study," Drug Safety, Springer, vol. 40(5), pages 443-455, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wiwan Worakunphanich & Sitaporn Youngkong & Wimon Suwankesawong & Claire Anderson & Montarat Thavorncharoensap, 2022. "Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries," IJERPH, MDPI, vol. 19(8), pages 1-12, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joanne Barnes & Jane L. Sheridan & Christine Yang Dong & Linda Härmark & Sunita Vohra & Mira Harrison-Woolrych, 2020. "Evaluation of a Web-Based, ‘Purchase Event’ Intensive Monitoring Method for Pharmacovigilance of Natural Health Products: Lessons and Insights from Development Work in New Zealand," Drug Safety, Springer, vol. 43(10), pages 981-998, October.
    2. Sieta T. de Vries & Judy Harrison & Patrick Revelle & Alicia Ptaszynska-Neophytou & Anna Radecka & Gowthamei Ragunathan & Phil Tregunno & Petra Denig & Peter G. M. Mol, 2019. "Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study," Drug Safety, Springer, vol. 42(7), pages 881-886, July.
    3. Ronald Kiguba & Henry Zakumumpa & Helen B. Ndagije & Norah Mwebaza & Ronald Ssenyonga & Phil Tregunno & Kendal Harrison & Munir Pirmohamed, 2023. "Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study," Drug Safety, Springer, vol. 46(6), pages 565-574, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:7:d:10.1007_s40264-018-0648-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.